ATE303162T1 - Natrium kanalblocker zusammensetzungen und deren verwendung - Google Patents

Natrium kanalblocker zusammensetzungen und deren verwendung

Info

Publication number
ATE303162T1
ATE303162T1 AT00923183T AT00923183T ATE303162T1 AT E303162 T1 ATE303162 T1 AT E303162T1 AT 00923183 T AT00923183 T AT 00923183T AT 00923183 T AT00923183 T AT 00923183T AT E303162 T1 ATE303162 T1 AT E303162T1
Authority
AT
Austria
Prior art keywords
sodium channel
channel blocking
blocking compositions
convulsion
disclosed
Prior art date
Application number
AT00923183T
Other languages
English (en)
Inventor
Nancy C Lan
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE303162T1 publication Critical patent/ATE303162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00923183T 1999-04-09 2000-04-10 Natrium kanalblocker zusammensetzungen und deren verwendung ATE303162T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12854399P 1999-04-09 1999-04-09
PCT/US2000/009387 WO2000061188A1 (en) 1999-04-09 2000-04-10 Sodium channel blocker compositions and the use thereof

Publications (1)

Publication Number Publication Date
ATE303162T1 true ATE303162T1 (de) 2005-09-15

Family

ID=22435837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923183T ATE303162T1 (de) 1999-04-09 2000-04-10 Natrium kanalblocker zusammensetzungen und deren verwendung

Country Status (9)

Country Link
US (3) US20020037926A1 (de)
EP (1) EP1169060B1 (de)
JP (1) JP2002541215A (de)
AT (1) ATE303162T1 (de)
AU (1) AU4334900A (de)
CA (1) CA2370030C (de)
DE (1) DE60022333T2 (de)
DK (1) DK1169060T3 (de)
WO (1) WO2000061188A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
CA2459470C (en) * 2001-09-03 2010-10-12 Patricia Salvati Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
WO2003072751A2 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
EP1438956A1 (de) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10359335A1 (de) * 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
US20050112183A1 (en) * 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
JP5285276B2 (ja) 2004-12-06 2013-09-11 シガ テクノロジーズ，インコーポレーテッド アレナウイルスに関連した感染をはじめとする出血熱ウイルスを処置するための、スルホニルセミカルバジド、セミカルバジドおよび尿素、その医薬組成物および方法
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
JP5271087B2 (ja) 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CN101034257B (zh) * 2007-04-06 2010-09-08 上海复旦天臣新技术有限公司 用于全息记录的感光薄膜及其制备方法
US20100249238A1 (en) * 2007-07-02 2010-09-30 Ruben Dario Sinisterra Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2528649A1 (de) * 2010-01-26 2012-12-05 Michael A. Evans Verfahren, vorrichtungen und mittel zur denervierung
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
EP2616441B1 (de) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridinverbindungen und ihre verwendung
JP2013540130A (ja) 2010-10-05 2013-10-31 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのキナゾリン化合物
US20130189354A1 (en) * 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
CA2822789A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
TW201331186A (zh) 2011-09-02 2013-08-01 Purdue Pharma Lp 作為鈉通道阻斷劑之嘧啶類
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US10004710B2 (en) * 2013-01-18 2018-06-26 Kemphys Ltd. Medicament for therapeutic treatment of neuropathic disease
EP3293184B1 (de) 2013-03-04 2020-12-16 Purdue Pharma L.P. Pyrimidincarboxamide als natriumkanalblocker
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
EP3039019B1 (de) 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decan-derivate und verwendung davon
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
WO2015099841A1 (en) 2013-12-23 2015-07-02 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
US9902726B2 (en) 2013-12-30 2018-02-27 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
CA2939501C (en) 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CA2948144A1 (en) 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
EP3154972A4 (de) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinanderivate und verwendung davon
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
US9958464B2 (en) * 2015-03-03 2018-05-01 Ark Diagnostics, Inc. Pregabalin immunoassays
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2022183051A1 (en) * 2021-02-26 2022-09-01 Vyluma Inc. Methods and formulations for topical administration of gabapentinoids
CN115554293A (zh) * 2021-07-01 2023-01-03 南京宁丹新药技术有限公司 一种药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US549692A (en) * 1895-11-12 And albert s
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
AR227521A1 (es) * 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
EP0942752B1 (de) * 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
ATE234298T1 (de) 1996-08-29 2003-03-15 Takeda Chemical Industries Ltd Zyklische etherverbindungen als natriumkanal- modulatoren
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
AU734490B2 (en) 1996-11-05 2001-06-14 Neuraxon Inc. A method for treating tension-type headache
FR2756738B1 (fr) * 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
NZ500590A (en) * 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU750578B2 (en) * 1997-09-08 2002-07-25 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
DE69842004D1 (de) 1997-11-21 2010-12-30 Purdue Neuroscience Co Substituierte 2-aminoacetamide und anwendung davon
DE19802327A1 (de) 1998-01-23 1999-07-29 Goedecke Ag Synergistische Arzneimittelzubereitung mit analgetischer Wirkung
EP1047414A1 (de) 1998-01-23 2000-11-02 Warner-Lambert Company Gabapentin und seine derivate zur behandlungen von muskel und skelett-schmerzen
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
WO1999039712A1 (en) 1998-02-04 1999-08-12 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
NZ508490A (en) * 1998-07-09 2003-08-29 Warner Lambert Co Use of a combination of a GABA analog and caffeine as an analgesic
ATE279188T1 (de) 1998-07-09 2004-10-15 Warner Lambert Co Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
UA72244C2 (en) * 1999-03-26 2005-02-15 Aryl-substituted pyrazols, imidazols, oxazols, thiazols, pyrrols and their use
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
BR0012934A (pt) * 1999-08-04 2003-07-29 Icagen Inc Processos para a redução de dor e de ansiedade
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
CA2459470C (en) 2001-09-03 2010-10-12 Patricia Salvati Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use

Also Published As

Publication number Publication date
EP1169060A1 (de) 2002-01-09
WO2000061188A1 (en) 2000-10-19
CA2370030A1 (en) 2000-10-19
DE60022333T2 (de) 2006-07-06
DE60022333D1 (de) 2005-10-06
AU4334900A (en) 2000-11-14
DK1169060T3 (da) 2006-01-16
US20040054005A1 (en) 2004-03-18
EP1169060B1 (de) 2005-08-31
JP2002541215A (ja) 2002-12-03
CA2370030C (en) 2007-08-14
US20020037926A1 (en) 2002-03-28
US20080318932A1 (en) 2008-12-25
WO2000061188A9 (en) 2002-02-14
US7393872B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
IS5890A (is) Aðferð til að gefa sýklalyf
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DK0909556T3 (da) Rosaceae-ekstrakt som bradykininantagonist
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
EA200101240A1 (ru) Использование мелатонина в медицине
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
PT1056458E (pt) Tratamento de dor cronica
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
TR199801024T2 (xx) Mide-ba��rsak d�zensizliklerinin engellenmesi ve iyile�tirilmesi i�in, bizmut ve bir ya da daha �ok antimikrobik madde ihitva eden bile�imler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169060

Country of ref document: EP